Los Angeles Capital Management LLC Acquires Shares of 39,462 Vaxcyte, Inc. $PCVX

Los Angeles Capital Management LLC bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 39,462 shares of the company’s stock, valued at approximately $1,283,000.

Several other institutional investors also recently modified their holdings of PCVX. Nisa Investment Advisors LLC increased its stake in shares of Vaxcyte by 10.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company’s stock valued at $112,000 after acquiring an additional 293 shares during the last quarter. US Bancorp DE raised its position in Vaxcyte by 7.2% in the 1st quarter. US Bancorp DE now owns 5,344 shares of the company’s stock valued at $202,000 after buying an additional 357 shares during the last quarter. Xponance Inc. raised its holdings in shares of Vaxcyte by 4.7% in the first quarter. Xponance Inc. now owns 9,320 shares of the company’s stock valued at $352,000 after purchasing an additional 415 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Vaxcyte by 1.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,635 shares of the company’s stock worth $1,119,000 after purchasing an additional 436 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its holdings in Vaxcyte by 2.2% during the first quarter. KLP Kapitalforvaltning AS now owns 23,000 shares of the company’s stock worth $868,000 after purchasing an additional 500 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Trading Up 1.0%

Shares of NASDAQ PCVX opened at $46.10 on Thursday. The firm has a market cap of $6.03 billion, a P/E ratio of -9.52 and a beta of 1.07. The business’s 50 day moving average is $38.90 and its 200-day moving average is $35.26. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $100.68.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period last year, the company earned ($0.83) EPS. Analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PCVX shares. BTIG Research reiterated a “buy” rating and set a $85.00 target price on shares of Vaxcyte in a report on Monday. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. Finally, The Goldman Sachs Group started coverage on shares of Vaxcyte in a report on Friday, September 12th. They set a “neutral” rating and a $38.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $102.00.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.